Navigation Links
OXYMATIC® 401A Electronic Oxygen Conserver

ProductsOXYMATIC® 401A Electronic Oxygen Conserver
Company CHAD Therapeutics, Inc.
Item OXYMATIC® 401A Electronic Oxygen Conserver
Features 
  • Alternate Breath Delivery with Built-in Aluminum Body Regulator with Brass Components (Continuous flow preset at 2 lpm)
  • Weighs approximately 1.2 lbs (544 grams) with the battery
  • Provides every-breath or alternate-breath delivery with a built-in regulator.
  • Offers 1-6 lpm flow equivalency settings to service a broad range of patients.
  • Delivers fixed pulse of oxygen within the first 200 milliseconds of inspiration.
  • Easy access to the battery compartment.
  • Description An All-In-One Conserver.

    Offers an average 5:1 increase in usage time at all settings.

    Allows the use of a standard cannula.

    The combination of the OXYMATIC conserver and lightweight cylinders offers ambulatory oxygen patients a superior alternative to liquid oxygen.

    Reliability backed by a 2-year warranty.

    NOTE: Each model has passed the ASTM PS 127-00 regulator ignition safety test.
    Info CHAD Therapeutics, Inc.
    Customer Service: (800) 423-8870
    Web site: http://www.chadtherapeutics.com

    Related medicine products :

    1. OXYMATIC® 401 Electronic Oxygen Conserver
    2. OXYMATIC® 411A Electronic Oxygen Conserver
    3. OXYMATIC® 411 Electronic Oxygen Conserver
    4. OXYMATIC® 411AF Electronic Oxygen Conserver
    5. SEQUOIA OXYMATIC® 302 Electronic Oxygen Conserver
    6. SEQUOIA OXYMATIC® 312 Electronic Oxygen Conserver
    7. OXYMATIC® 2400 Electronic Oxygen Conserver
    8. SEQUOIA OXYMATIC® 311 Electronic Oxygen Conserver
    9. MaximEyes Practice Management and Electronic Medical Records Software Solutions
    10. PRAXIS® Electronic Medical Records v. 2.19
    11. MaximEyes Optometric & Ophthalmology Software for Practice Management and Electronic Medical Records
    Inquire
    Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the in vitro determination of Measles IgM antibodies in human serum. For in vitro diagnostic use. High complexity test.
    ...nzymelinked Immunosorbent Assays(ELISA) is intende... of IgG antibody to Measles Rubeola) virus in huma... the determination of immune status. Paired sera, ...te seroconversion or a significant rise in antibod...
    The Diagnostic Automation, Inc. (DAI) Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the in vitro determination of IgM antibody to Measles in human serum.
    Medicine Products:
    (Date:5/16/2008)...eath the lining of the uterus (submucosal) are mor...terine artery embolization (UAE) but usually dont ...y. , The study included 49 patients with 140 fi... after UAE. The study found that 39 of these were ...ial cavity after UAE, said Sachit Verma, MD, lead ...
    (Date:5/16/2008)...titute with 10,000 Sensual O Condom Packs Donatio...Fundraiser, LOS ANGELES, May 16 /PRNewswire/ -- O...t J Kwon known best for his hit song "Everybody in...rban Health Institute (UHI) with,10,000 Sensual O ...ation is,being made to promote the launch of the A...
    (Date:5/16/2008)...- Huntsworth plc (LSE: HNT), "the Group",a leadin...mmunications,group headquartered in London, releas...he Group,s performance in the first quarter 2008 (...nt follows below., 15 May 2008, ...Interim Management Statement, Record n...
    (Date:5/16/2008)... /PRNewswire-FirstCall/ -- Nationwide,Health Prope...otion of David,M. Boitano to Senior Vice President...remendous contribution to NHP over the last severa...th and diversification strategy,successes. Dave ha...e,investments for NHP, leveraging his vast experie...
    Breaking Medicine News(10 mins):Health News:Everybody in the Club Scream O! 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4Health News:David M. Boitano Promoted to Senior Vice President 2
    ...handigarh is all set to turn into a "no-smoking zo...horities, the ban would be fully enforced from Jul.... Smoking kills over a million of the 250 million ...country. The establishment says it will not make...
    ... new study has found that weight management progra...easing weight, body fat, body mass index (BMI) in ...ement program developed by researchers at Yale Sch...at plummeting weight, body fat, BMI and insulin se...
    ...ndian neuroscientists are part of an international...s of mental retardation and autism in mice, raisi...fects one in 500 children. Researchers at the Nat... (NCBS) and National Institute of Mental Health an...
    ...learly a new wind is blowing across in three key a... are sick, literally and metaphorically, one might...respective governments seem to have failed the peo...king off a major healthcare crisis. The powers-tha...
    Other Medicine News:Health News:Chandigarh Set to Be No-smoking Zone from July 15 2Health News:Bright Bodies Weight Program Lowers Diabetes Risk, BMI in Obese Kids 2Health News:Research Shows Way for Drug Therapy for Autism 2Health News:Back to Basics in Health in Advanced Countries Now 2Health News:Back to Basics in Health in Advanced Countries Now 3Health News:Back to Basics in Health in Advanced Countries Now 4
    (Date:5/15/2008)...ITA SPRINGS, Fla., May 15 /- Tigris P... of a Cooperative Research and,Development Agreeme...) to,collaborate on clinical and preclinical devel...ase I development. AFP-464 is converted to,metabol...3 activation and,apoptosis., This is part of a fo...
    (Date:5/15/2008)...rable Opportunity Remains for an Antiplatelet Ther...ding than the Combination of Plavix/Iscover an... Resources, WALTHAM, Mass., May 15 /...esearch and advisory firms for pharmaceutical and,...illy,s Effient offers,improvement in patient compa...
    (Date:5/15/2008)...ine Data Expected soon after CEA Trial data report... -, SAN FRANCISCO, May 15 /PRNewswire-FirstCall... biotechnology company focused on the development ...isease, announced today that,it has completed pati...),study. The ACS study is one of three Phase 2 tri...
    (Date:5/15/2008)...ta Presented at the 21st Annual Meeting of The Ame...ncology (ASPHO) Meeting -, IRVINE, Calif., May 15...ompany) (Nasdaq: IDMI ) today announced the prese...s program evaluating mifamurtide (L-MTP-PE) in,pat...ression of,osteosarcoma, a rare and often fatal bo...
    Breaking Medicine Technology:Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 2IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 4IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 6Cyprotex Introduces New Product Line Cloe 28R 29 Select a Portfolio of Bespoke ADME and PK Services 4341 1Cyprotex Introduces New Product Line Cloe 28R 29 Select a Portfolio of Bespoke ADME and PK Services 4341 2Households with kids with autism likely to earn less 15730 1Households with kids with autism likely to earn less 15730 2Households with kids with autism likely to earn less 15730 3Climate and cholera 2713 1CompareNetworks Inc Fuels Growth by Raising Round of Financing 15726 1CompareNetworks Inc Fuels Growth by Raising Round of Financing 15726 2
    ...h Copaxone Plus Minocycline Showed Substantial,Red...,Relapsing-Remitting Multiple Sclerosis , Combinat...n,Lesions and Was Well Tolerated , KANSAS CITY, Mo...-blind study showed that a combination of Copaxone...l antibiotic,minocycline reduced T1 Gadolinium (Gd...
    ...o.--(BUSINESS WIRE)--May 4, 2007 - New data from a...ination of,COPAXONE(R) (glatiramer acetate injecti...uced T1 Gadolinium (Gd)-enhancing lesions,of the b...e,relapsing-remitting multiple sclerosis (RRMS), a...mpared to those receiving,COPAXONE(R) alone. Addit...
    Other Medicine Technology:Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5